A Study on Rheumatoid Arthritis Patients Treated With Rituximab

Completed

• Conditions: Rheumatoid Arthritis
• Interventions: Drug: Rituximab

• Registration Number: NCT02622503
• Lead Sponsor: Hoffmann-La Roche

Brief Summary

The purpose of the study is to obtain an overall picture of rituximab treatments and treatment responses in RA patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-04
• Primary Completion: 2008-08
• Study Completion: 2008-08
• Study First Submitted: 2015-12-02
• Study First Submitted QC: 2015-12-02
• Study First Posted: 2015-12-04
• Status Verified: 2016-12
• Last Update Submitted: 2016-12-12
• Last Update Posted: 2016-12-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 81

Inclusion Criteria

• Rheumatoid arthritis (RA) patients treated with rituximab in Finland

Read More

Exclusion Criteria

• Not applicable

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients with rheumatoid arthritis	Rituximab	Patients with rheumatoid arthritis receiving rituximab will be observed for treatment responses.

Primary Outcome Measures

Name	Time	Method
Information on previous RA treatments	3 months
Information on rituximab treatment responses	3 months
Information on concomitant medications	3 months